Sirtex Medical Inc.

Sirtex develops oncology treatments using small particle technology to improve outcomes for patients with cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation during minimally invasive Selective Internal Radiation Therapy. Data shows a 7.9-month improvement in Progression-Free Survival in the liver for patients with unresectable mCRC treated 1st-line with SIR-Spheres Y-90 resin microspheres plus standard chemotherapy. The results of the 530-patient SIRFLOX randomized controlled study opens new treatment possibilities for patients whose tumors cannot be resected. Learn more about the SIRFLOX study and its significance for patients at

300 Unicorn Park Drive
Woburn, Massachusetts 01801
(888) 474-7839